Salivary gland second cancer after bone sarcoma treatment

Alessandra Longhi, Costantino Errani, Marco Gambarotti, Christina Ferrari, Jennifer Kreshak, Georgios N. Panagopoulos, Andreas F. Mavrogenis, Davide Donati

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Second malignant neoplasms (SMN) or second cancers may occur in 2–5 % of childhood cancer survivors within 5–25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. Materials and methods: We retrospectively studied all patients with osteosarcoma and Ewing’s sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing’s sarcoma patients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. Results: The 10-year incidence of SMN was 3.6 %; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 %; there were five male and two female patients with a mean age of 19 years (range 13–28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51–97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. Conclusions: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.

Original languageEnglish
Pages (from-to)1201-1204
Number of pages4
JournalEuropean Journal of Orthopaedic Surgery and Traumatology
Volume25
Issue number7
DOIs
Publication statusPublished - Oct 3 2015

Fingerprint

Salivary Gland Neoplasms
Bone Neoplasms
Second Primary Neoplasms
Sarcoma
Bone and Bones
Therapeutics
Ewing's Sarcoma
Osteosarcoma
Drug Therapy
Survivors
Incidence
Histology
Leukemia
Breast Neoplasms
Submandibular Gland
Salivary Glands

Keywords

  • Chemotherapy
  • Ewing’s sarcoma
  • Osteosarcoma
  • Salivary gland neoplasms
  • Second cancer

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Salivary gland second cancer after bone sarcoma treatment. / Longhi, Alessandra; Errani, Costantino; Gambarotti, Marco; Ferrari, Christina; Kreshak, Jennifer; Panagopoulos, Georgios N.; Mavrogenis, Andreas F.; Donati, Davide.

In: European Journal of Orthopaedic Surgery and Traumatology, Vol. 25, No. 7, 03.10.2015, p. 1201-1204.

Research output: Contribution to journalArticle

@article{808b244862e447eeb04a368fdf3da6b4,
title = "Salivary gland second cancer after bone sarcoma treatment",
abstract = "Purpose: Second malignant neoplasms (SMN) or second cancers may occur in 2–5 {\%} of childhood cancer survivors within 5–25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. Materials and methods: We retrospectively studied all patients with osteosarcoma and Ewing’s sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing’s sarcoma patients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. Results: The 10-year incidence of SMN was 3.6 {\%}; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 {\%}; there were five male and two female patients with a mean age of 19 years (range 13–28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51–97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. Conclusions: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.",
keywords = "Chemotherapy, Ewing’s sarcoma, Osteosarcoma, Salivary gland neoplasms, Second cancer",
author = "Alessandra Longhi and Costantino Errani and Marco Gambarotti and Christina Ferrari and Jennifer Kreshak and Panagopoulos, {Georgios N.} and Mavrogenis, {Andreas F.} and Davide Donati",
year = "2015",
month = "10",
day = "3",
doi = "10.1007/s00590-015-1662-x",
language = "English",
volume = "25",
pages = "1201--1204",
journal = "European Journal of Orthopaedic Surgery and Traumatology",
issn = "1633-8065",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Salivary gland second cancer after bone sarcoma treatment

AU - Longhi, Alessandra

AU - Errani, Costantino

AU - Gambarotti, Marco

AU - Ferrari, Christina

AU - Kreshak, Jennifer

AU - Panagopoulos, Georgios N.

AU - Mavrogenis, Andreas F.

AU - Donati, Davide

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Purpose: Second malignant neoplasms (SMN) or second cancers may occur in 2–5 % of childhood cancer survivors within 5–25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. Materials and methods: We retrospectively studied all patients with osteosarcoma and Ewing’s sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing’s sarcoma patients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. Results: The 10-year incidence of SMN was 3.6 %; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 %; there were five male and two female patients with a mean age of 19 years (range 13–28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51–97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. Conclusions: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.

AB - Purpose: Second malignant neoplasms (SMN) or second cancers may occur in 2–5 % of childhood cancer survivors within 5–25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. Materials and methods: We retrospectively studied all patients with osteosarcoma and Ewing’s sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing’s sarcoma patients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. Results: The 10-year incidence of SMN was 3.6 %; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 %; there were five male and two female patients with a mean age of 19 years (range 13–28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51–97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. Conclusions: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.

KW - Chemotherapy

KW - Ewing’s sarcoma

KW - Osteosarcoma

KW - Salivary gland neoplasms

KW - Second cancer

UR - http://www.scopus.com/inward/record.url?scp=84942878340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942878340&partnerID=8YFLogxK

U2 - 10.1007/s00590-015-1662-x

DO - 10.1007/s00590-015-1662-x

M3 - Article

VL - 25

SP - 1201

EP - 1204

JO - European Journal of Orthopaedic Surgery and Traumatology

JF - European Journal of Orthopaedic Surgery and Traumatology

SN - 1633-8065

IS - 7

ER -